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Abstract
Elisidepsin (elisidepsin trifluoroacetate, IrvalecH, PM02734) is a new synthetic depsipeptide, a result of the PharmaMar
Development Program that seeks synthetic products of marine origin-derived compounds. Elisidepsin is a drug with
antiproliferative activity in a wide range of tumors. In the present work we studied and characterized the mechanisms
associated with sensitivity and resistance to elisidepsin treatment in a broad panel of tumor cell lines from breast and
pancreas carcinomas, focusing on different factors involved in epithelial-mesenchymal transition (EMT) and the use of HER
family receptors in predicting the in vitro drug response. Interestingly, we observed that the basal protein expression levels
of EMT markers show a significant correlation with cell viability in response to elisidepsin treatment in a panel of 12 different
breast and pancreatic cancer cell lines. In addition, we generated three elisidepsin treatment-resistant cell lines (MCF-7,
HPAC and AsPC-1) and analyzed the pattern of expression of different EMT markers in these cells, confirming that acquired
resistance to elisidepsin is associated with a switch to the EMT state. Furthermore, a direct correlation between basal HER3
expression and sensitivity to elisidepsin was observed; moreover, modulation of HER3 expression levels in different cancer
cell lines alter their sensitivities to the drug, making them more resistant when HER3 expression is downregulated by a
HER3-specific short hairpin RNA and more sensitive when the receptor is overexpressed. These results show that HER3
expression is an important marker of sensitivity to elisidepsin treatment.
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Introduction
Elisidepsin (elisidepsin trifluoroacetate, IrvalecH, PM02734), a
synthetic cyclic peptide originally isolated from the marine mollusk
Elysia rufescens [1], is a cytotoxic anticancer agent [2,3,4].
Elisidepsin does not exhibit a linear cytotoxic dose-response and
acts independently of the multidrug resistant status of various
tumor cell lines [5]. The primary mechanisms of action of
elisidepsin have not been identified, although multiple cellular
targets have been described, many of which, due to the
hydrophobic nature of the compound, are associated with the
cell membrane [6,7,8,9].
One of the several targets that are proposed to be involved in
the cellular response to elisidepsin treatment is the human
epidermal growth factor receptor family (HER) with several
in vitro studies identifying HER3 and the downstream signaling
pathway PI3K-AKT as major determinants of the cytotoxic
activity of elisidepsin [10,11]. Moreover, it has recently been
postulated that elisidepsin induces the redistribution of HER3
from the plasma membrane to intracellular vesicles without
comparable effects on HER1 and HER2, suggesting that it is
HER3 that plays a key role in determining sensitivity to the drug
[9].
On the other hand, specifically in relation to epithelial cells, one
of the best-described processes that affects the composition of the
cell membrane is that of the epithelial-mesenchymal transition
(EMT), which is where cells downregulate their cell-cell junctions
and acquire spindle cell morphology [12,13]. The EMT plays an
important role in development [14,15], particularly in gastrulation
and neural crest migration [14]. A critical component is the loss of
type I cadherins that maintain stable cell-cell contacts through
adherens junctions and desmosomes [16,17]. To preserve cellular
shape and polarity, the intracellular domains of cadherins connect
to the actin cytoskeleton through a-catenin and b-catenin
[18,19,20].
In most cases, this is associated with transcriptional repression of
E-cadherin [21,22], which in turn increases cell invasiveness
[13,22,23,24]. Several specific repressor factors have been
identified, such as the zinc-finger domain-containing Snail and
Slug factors [25], and the basic helix-loop-helix factor Twist, all of
which can bind to the so-called E-boxes within the cadherin-1
(CDH1) gene promoter [25,26]. Their function is regulated by
oncogenic pathways, particularly by AKT, glycogen synthase
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kinase 3b (GSK-3b), NF-kB, RAS and SRC, some of which have
been described as potential elisidepsin targets [15,27,28].
In this scenario, until the proposed above targets are validated,
robust models that permit the identification novel predictive
biomarkers are essential. To this end, and due to the increasing
evidence supporting a role for the EMT in the progression of
many cancer types, with critical roles in invasion and metastatic
dissemination, we decided to study both HER3 and EMT as new
predictive markers of elisidepsin treatment sensitivity in a panel of
breast and pancreatic cell lines.
In this report, we show that continued exposure to elisidepsin is
correlated with a downregulation of epithelial markers in four
different cancer cell types (pancreatic, breast, lung and colon). This
behavior is further accompanied by several morphological and
signaling changes, resulting in the upregulation of mesenchymal
markers. Furthermore, we investigated the effect of the drug on
the expression of HER proteins and systematically compared the
elisidepsin sensitivity of cell lines overexpressing and knocking-
down HER3 receptor. Finally, we identified HER3 expression as
the most important sensitivity marker of elisidepsin studied.
Results
Cancer Cell Line Sensitivity to Elisidepsin
We performed cell viability assays in a panel of 12 cell lines (6
breast cancer cell lines and 6 pancreatic carcinoma cell lines) to
determine if there was a correlation between epithelial or
mesenchymal expression markers and cell sensitivity to elisidepsin.
Cells were treated with increasing concentrations of the compound
for 72 h. The half maximal (50%) inhibitory concentration (IC50)
values for elisidepsin, as measured by a crystal violet assay using a
spectrophotometer, ranged from 0.075 to 14 mM within the cell
line panel (Fig. 1A).
According to the results of a previous paper from our lab and
others [27,28], only those cells with an IC50 value under or equal
to 1 mM are considered sensitive to the elisidepsin. MDA-MB-231,
PANC-1 and MiaPaCa-2 cell lines were the only cell lines that had
an IC50 value higher than 1 mM (6.5, 7.5 and 14 mM,
respectively). The other cell lines were classed as being sensitive
to the drug (with IC50 values ranging from 0.075 to 0.6 mM).
The effect of elisidepsin is not considered to be time-dependent
as no significant difference in the ratio of IC50 values was seen by
Sewell et al. [7] following 1 h exposure and continuous exposure.
However, when we treated the cells with continuous exposure to a
subtoxic dose (i.e. lower than the IC50) the cells grew more slowly
than the parental ones (Fig. 1B). Recent studies have shown that
the potent cytotoxic activity of elisidepsin is exerted very rapidly
through insertion of the drug molecule into the plasma membrane,
which causes a drastic loss in membrane integrity [8]. However,
we found that, despite elisidepsin-induced loss of membrane
integrity, those cells that remained alive after treatment could
recover and proliferate again (Fig. S1). This was shown by treating
MCF-7 cancer cell lines with 1 mM elisidepsin for 4 h, removing
the drug and measuring proliferation at different time points.
More than 50% of cells died after 4 h drug treatment but when the
media was replaced the cells recovered and their viability
increased.
Correlation between EMT Markers and Elisidepsin Cell
Sensitivity
In order to evaluate EMT protein expression levels and
correlate them with the sensitivity of the cell lines to elisidepsin,
we performed different analyses using western blot, immunoflu-
orescence and immunohistochemistry (IHC) in a panel of 12 cell
lines. The protein expression of E-cadherin, b-catenin, vimentin,
Slug, Snail and Twist-1 were assessed by immunocytochemical
and western blot analysis, while the protein expression of E-
cadherin, b-catenin, and vimentin were evaluated by immunohis-
tochemical analysis.
We aimed to determine whether the various elisidepsin-sensitive
cancer cell lines shared similar basal levels of EMT genes. In the
breast cancer cell lines we found E-cadherin expression in the
sensitive cell lines. All cell lines had detectable expression of b-
catenin, whereas Slug expression was variable and not related to
their sensitivity to elisidepsin. Furthermore, Snail expression was
only found in MDA-MB-435, and all the cell lines that exhibited
levels of Twist-1 and vimentin were less sensitive to the drug
(Figs. 2A–C). In contrast, elisidepsin-sensitive pancreatic carcino-
ma cell lines expressed E-cadherin and b-catenin, whereas the less
sensitive cells expressed Slug. Lastly, Snail, Twist-1 and vimentin
expression was found in sensitive and insensitive cell lines alike
(Figs. 3A–C). To summarize, E-cadherin protein was significantly
expressed in the sensitive cell lines independently of their tumoral
origin (Mann-Whitney test: p = 0.0364; Fig. S2), and vimentin was
significantly expressed in the less sensitive ones (Mann-Whitney
test: p = 0.0364). On the other hand, Twist-1 and Snail proteins
were found in all less sensitive cell lines (Mann Whitney test: p
= 0.0636 and p = 0.1000, respectively), with the exception of two
sensitive cell lines that were positive for vimentin expression
(CFPAC and AsPC-1), one sensitive cell line that was positive for
Twist-1 expression (CFPAC) and another one that was positive for
Snail expression (SKBR3).
HER3 Expression Levels Correlate with Elisidepsin Cell
Sensitivity
The primary mechanisms of action of elisidepsin remain to be
elucidated but we and other groups have found that after 4 h
treatment with 1 mM elisidepsin, HER3 receptor levels are
downregulated in a panel of different cell lines, including lung,
breast, melanoma and colon carcinomas [10,11]. To determine if
HER3 protein expression levels correlate with the sensitivity of the
cell lines to elisidepsin, we performed IHC (Fig. 4A) and western
blot analysis (Fig. 4B) in all cell lines. Cell lines that were less
sensitive to elisidepsin had little to no HER3 while sensitive cell
lines expressed significantly increased levels of this protein (Mann-
Whitney test: p = 0.0091; Fig. S3). In addition, others members of
the HER family were checked by western blot (Fig. 4B) but no
correlations with elisidepsin sensitivity were found with HER1,
HER2 and HER4 (Mann-Whitney test: p = 0.7273, p = 0.5182
and p = 0.8909, respectively).
Acquired Resistance to Elisidepsin Induces an EMT
Phenotype
Three elisidepsin-resistant cancer cell lines [one breast (MCF-7)
and two pancreatic (HPAC, AsPC-1)] were generated by
continuous exposure to increasing concentrations of the drug
(see Material and Methods). Cancer cell lines were exposed to
elisidepsin at a starting concentration of its IC50. Elisidepsin
concentration was increased every week until cells became
resistant to the drug, after approximately 12 months in the case
of MCF-7, and after approximately 4 months in the case of HPAC
and AsPC-1. The morphology of the resistant cancer cell lines was
modified after continuous exposure to the drug when compared to
that of the parental cell lines (data not shown). Our hypothesis was
that the loss of epithelial markers observed in our panel of cancer
cell lines could be responsible for the resistance to elisidepsin
EMT and HER3 Predicts Elisidepsin Sensitivity
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treatment, which would in turn result in the acquisition of
mesenchymal markers in these cells.
We then performed western blot analysis of the cancer cell lines
with acquired resistance and compared them to the corresponding
parental control cells. We identified that the three different cancer
cell types with acquired resistance to elisidepsin had altered basal
levels of EMT markers (Fig. 5A). All resistant cell lines showed
decreased E-cadherin, c-catenin and increased vimentin and
Twist-1 expression. b-catenin expression was downregulated in the
resistant HPAC and AsPC-1 cancer cell lines but upregulated in
the MCF-7. In contrast, levels of Slug and Snail were upregulated
in the resistant cancer cell lines HPAC and AsPC-1 but no
differences were found in the breast carcinoma MCF-7 cell line.
We also performed the same approach in different resistant cell
lines from colon and lung (HCT116 and A549, respectively) with
similar results (Fig. S4). Analysis by western blot confirmed that
acquired resistance to elisidepsin is associated with a switch to the
EMT state.
Furthermore, we wanted to see if these cells also showed
different expression levels of HER family members and proteins of
their signaling pathways. We observed that the levels of all HER
family members and their downstream signaling partners were
downregulated in all resistant cancer cell lines (Figs. 5B and S4). A
suppression of downstream signaling was similarly seen in the
breast and pancreatic resistant cell lines, and the same expression
pattern was also observed in other colon and lung resistant cell
lines, highlighting the relevance of this phenomena.
Modulation of HER3 Affects Cancer Cell Line Sensitivity to
Elisidepsin
Based on previous studies from our group and others
demonstrating that elisidepsin downregulates the HER3 receptor
tyrosine kinase and that high expression of HER3 is prevalent in a
broad number of different tumor cells, we investigated if
modulation of protein expression levels of the HER3 receptor
Figure 1. Elisidepsin sensitivity. A) Elisidepsin IC50s were determined in a panel of breast (left) and pancreatic (right) cancer cell lines using a
crystal violet assay. Cells were exposed to elisidepsin for 72 h. Results are shown as the mean 6 SD of at least three independent experiments. B) Cell
proliferation in parental and subtoxic elisidepsin-treated cells. Cumulative numbers of cell divisions [shown as population doubling level (PDL)] are
shown for MCF-7 and MiaPaCa-2 cells until passage 5. Proliferation of MCF-7 (IC50:0.4 mM) and MiaPaCa-2 (IC50:14 mM) cells was suppressed when
elisidepsin was added to the culture at subtoxic doses (0.2 and 1 mM, respectively). The number of MiaPaCa-2 and MCF-7 seeded cells were 1.256105
and 1.46105, respectively. Each growth curve was performed at least twice with similar results, SDs are shown, and each time point was performed in
duplicate. P, passage.
doi:10.1371/journal.pone.0053645.g001
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affects sensitivity to elisidepsin in a panel of tumor cell lines with
variable expression of this receptor.
To examine this experimentally, we utilized a shRNA construct
to stably reduce HER3 expression in a panel of cell lines (Fig. 6).
Stable clones of HER3 shRNA and LUC shRNA (control) vector-
transfected cells were selected and examined for expression of
HER3. As expected, levels of HER3 were significantly reduced in
HER3-transfected cells, but not in those containing the pLKO
Figure 2. Expression of EMT markers associated with elisidepsin sensitivity in breast cancer cell lines. Protein expression levels of
different EMT markers were evaluated by immunocytochemistry (A), western blot (B) and IHC (C). A) Immunocytochemistry of two epithelial (E-
cadherin and b-catenin) and four mesenchymal markers (vimentin, Slug, Snail and Twist). Magnification 100x. B) E-cadherin, b-catenin, Slug, Snail,
Twist, vimentin and b-actin (loading control) were detected by western blot analysis using 50 mg of total protein. C) Basal levels of E-cadherin, b-
catenin and vimentin were analyzed by IHC. Magnification 20x. Each experiment was performed at least in duplicate.
doi:10.1371/journal.pone.0053645.g002
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LUC shRNA vector alone, indicating that the decrease in HER3
was not due to non-specific effects of introducing shRNA into the
cells. Next, cell viability assays were performed to analyze
elisidepsin sensitivity in the generated cells. Figure 6 shows that
cells that have reduced levels of HER3 due to shRNA-mediated
knockdown of its expression showed loss of sensitivity to elisidepsin
treatment in comparison to control cell lines.
To investigate whether ectopic HER3 expression affects the
elisidepsin sensitivity of low HER3-expressing cells, the levels of
HER3 were increased by transfecting cells with a cDNA encoding
HER3, which resulted in increased sensitivity of the cells to
elisidepsin. In comparison to control cells transfected with a LUC
vector, decreased cell viability was noted in HER3-transfected cells
Figure 3. Expression of EMT markers associated with elisidepsin sensitivity in pancreatic cancer cell lines. E-cadherin, b-catenin,
vimentin, Slug, Snail and Twist basal expression levels were evaluated by immunocytochemistry (A) and western blot (50 mg of protein/lane) (B).
Magnification 100x. Membranes were stripped and reprobed with anti-b-actin as an internal control. C) E-cadherin, b-catenin and vimentin protein
expression levels were evaluated by IHC. Magnification 20x. These analyses were performed in duplicate.
doi:10.1371/journal.pone.0053645.g003
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(Fig. 7). Altogether, these results suggest that ectopic HER3
expression sensitizes these cells to elisidepsin treatment.
Discussion
Elisidepsin is a novel marine compound with a potent cytotoxic
activity in various tumor cell lines. The mechanisms of actions of
this compound remain poorly understood, although several targets
Figure 4. HER3 expression levels correlate with cell sensitivity to elisidepsin. A) Cell pellets were fixed in formalin, embedded in paraffin
and a HER3 IHC was performed. Cell lines more sensitive to elisidepsin had significant HER3 levels. Magnification 40x. B) Basal expression levels of HER
family members were analyzed by western blot; an association between HER3 expression and elisidepsin sensitivity was observed (Mann-Whitney
test: p = 0.0091; Fig. S3). Cell lines less sensitive to elisidepsin (MDA-MB-231, PANC-1 and MiaPaCa-2) did not show significant HER3 protein levels,
while PANC-1 and MiaPaCa-2 cell lines show levels of other HER family members. No correlation was observed with HER1, HER2 and HER4 expression
levels (Fig. S3). These protein expression levels were analyzed in duplicate and 50 mg of protein of cell lysate were loaded in each lane.
doi:10.1371/journal.pone.0053645.g004
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have been proposed to be involved in the cellular response to
elisidepsin treatment, such as fatty acid-containing ceramides, fatty
acid 2-hydroxylase (FA2H), lysosomes, lipid rafts and epithelial
growth factor receptors, including the HER receptors
[10,29,30,31,32,33].
In the present study we explored whether basal levels of EMT
markers and HER receptor proteins could be predictive markers
for elisidepsin treatment. The role of the cell membrane as an
important target of elisidepsin was studied in breast and pancreas
cancer cell lines. Basal levels of EMT protein expression markers
Figure 5. Acquired resistance to elisidepsin induces an EMT phenotype. A) Cells were lysed, proteins were extracted and western blots were
performed with equal amounts of cell lysate (50 mg protein). Expression of epithelial (E-cadherin, b-catenin, c-catenin)- and mesenchymal (vimentin,
Slug, Snail, Twist)-associated proteins differentiates between elisidepsin-sensitive and elisidepsin-resistant cell lines. b-actin was used as an internal
control. These western blots were performed in triplicate. B) Expression levels of HER1, HER2, HER3, HER4, pAkt, and pMAPK were analyzed by
western blot using 50 mg of protein cell lysate. The membranes were stripped and reprobed with anti-b-actin to verify equal protein loading. C,
control; R, resistance.
doi:10.1371/journal.pone.0053645.g005
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showed a significant correlation with the cell viability response to
elisidepsin treatment in a panel of 12 different cancer cell lines.
The epithelial marker E-cadherin protein was significantly
expressed in the sensitive cell lines (p = 0.0364) while expression
of the mesenchymal markers vimentin, Twist-1 and Snail, was
found in all cell lines with reduced sensitivity to the drug.
Furthermore, this study showed that continuous exposure to
elisidepsin correlates with a downregulation of epithelial markers
in 4 different cancer cell types (breast, pancreas, lung and colon).
Loss of epithelial markers was further evidenced by the detection
of morphological changes in the cells. These changes, which were
observed after continuous long-term exposure of different cell
types to elisidepsin, suggest that the drug is able to modify the
composition of the plasma membrane. This behavior was further
accompanied by signaling changes, resulting in the upregulation of
mesenchymal markers. This analysis confirmed that acquired
resistance to elisidepsin is associated with a switch to the EMT
state.
On the other hand, regarding HER family receptors, we
observed an association between HER3 protein expression and
sensitivity to elisidepsin treatment in a variety of cell lines (p
= 0.0091). The other members of the HER family were also
checked by western blotting and we did not find any significant
correlation. Interestingly, HER4 expression was observed in 4 out
of 5 elisidepsin-sensitive breast cancer cell lines, and further studies
that include more breast cancer cell lines are necessary to establish
the potential predictive marker of the HERs for elisidepsin
sensitivity in breast cancer models. Cell lines that were less
sensitive to elisidepsin had lower or undetectable levels of HER3 in
comparison with sensitive cell lines, supporting a hypothetical role
for HER3 in the cellular response to this drug, although other
authors propose that HER3 is part of a secondary process
involving cell membrane alterations due to elisidepsin treatment
[9] or to a reduction in the proliferation rate in those cells with less
HER3 expression. Importantly, we could not discard the
possibility that elisidepsin may affect other signaling pathways,
Figure 6. Loss of HER3 expression decreases the sensitivity to elisidepsin treatment. Cell viability after treatment with various
concentrations of elisidepsin for 72 h was determined in SKBR3 (A), MCF-7 (B), MDA-MB-231 (C), MDA-MB-435 (D), BT474 (E), BxPC-3 (F), HPAC (G) and
AsPC-1 (H) cells. HER3 expression was downregulated with shRNA (grey squares); LUC shRNA transfected cells were used as the control (black
diamonds). Mean, SD, and IC50 values are shown from three independent experiments. Cell viability was measured using a crystal violet assay. Before
performing the viability experiments, all cell lines were checked by western blot using 50 mg of protein to confirm their levels of HER3 expression.
doi:10.1371/journal.pone.0053645.g006
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such as those of the transforming growth factor-b (TGF-b) family,
which potentially plays a role in both EMT and HER3 expression.
Malignant cells commonly possess overactive signal transduc-
tion cascades that provide potential selective targets for antitumor
drugs [34]. Based on previous studies in which we observed
elisidepsin treatment-induced HER3 downregulation [11], in
addition to the fact that high expression of the HER3 receptor
tyrosine kinase is prevalent in tumor cells, including cancers of the
breast, ovary and prostate [35,36,37,38,39,40,41,42], we correlat-
ed basal protein expression levels of HER3 with sensitivity to
elisidepsin in a panel of tumor cell lines with variable expression of
this receptor and found that downregulation of HER3 exerted a
protective effect against elisidepsin cytotoxicity. In fact, HER3
significantly increases cell sensitivity in all cell lines studied,
supporting previous indications that HER3 could be a good
predictive marker of cell sensitivity to elisidepsin.
In summary, we present solid evidence that sensitivity to
elisidepsin correlates with HER3 receptor expression. However, it
remains to be elucidated why elisidepsin affects HER3 and why its
effects depend on HER3 expression.
Materials and Methods
Chemicals
Elisidepsin (Figure S5) was obtained from PharmaMar (Madrid,
Spain) as a lyophilized powder. It was reconstituted in dimethyl
sulfoxide (DMSO; Sigma-Aldrich, Taufkirchen, Germany)/etha-
nol (1:1) as a 1 mM stock solution, which was stored in aliquots at
220uC. Drug dilutions were freshly prepared before each
experiment in order to avoid degradation.
Cells and Cell Culture
Cell lines were obtained from the American Type Culture
Collection (VA, USA). The following cell lines were maintained in
RPMI 1640 with 4 mM L-glutamine: MDA-MB-435, MDA-MB-
231, MCF-7 and SKBR3 (breast carcinoma), and AsPC-1 and
BxPC-3 (pancreas carcinoma). The following cell lines were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) with
4 mM L-glutamine and 4.5 g/L glucose: HCT116 (colon carci-
noma), MDA-MB-468 (breast carcinoma), and HPAC, PANC-1
and MiaPaCa-2 (pancreas carcinoma). A549 (lung carcinoma) was
maintained in Ham’s F-12 medium supplemented with 1 mM L-
glutamine. Finally, DMEM:Ham’s F12 (1:1 mixture) supplement-
ed with 1 mM L-glutamine was used to maintain BT474 (breast
carcinoma). HPAC resistant to elisidepsin 8 mM and AsPC-1
resistant to elisidepsin 4.5 mM were generated by continuous
exposure to the drug for ,4 months, while HCT 116 resistant to
elisidepsin 100 mM, A549 resistant to elisidepsin 25 mM, and
MCF-7 resistant to elisidepsin 4 mM were generated by continuous
exposure to the drug for ,1 year. The media for all cell lines were
supplemented with 10% fetal bovine serum, 100 U/mL penicillin,
100 mg/mL streptomycin and 10 mM HEPES and were cultured
in a 37uC humidified atmosphere containing 95% air and 5%
CO2.
Western Blots
Immediately prior to use in western blotting, cultured cells were
lysed and collected in lysis buffer. Lysates were centrifuged and
supernatants were collected for protein concentration determina-
tion using the Bradford (Bio-Rad Protein Assay, Munich,
Germany) method. Equal amounts of protein were separated by
8% sodium dodecyl sulfate (SDS)-polyacrylamide gel electropho-
Figure 7. Upregulation of HER3 increases elisidepsin sensitivity. Cell viability after treatment with various concentrations of elisidepsin for
72 h was determined in PANC-1 (A), MiaPaCa-2 (B), MDA-MB-435 (C) and MDA-MB-231 (D) cells. Stable cell lines with an upregulation of HER3
expression (with the pIRES HER3) are shown with white circles while black diamonds are used for LUC-transfected control cells (with the pIRES-LUC).
Mean, SD, and IC50 values are shown from three independent experiments. Cell viability was measured by a crystal violet assay. Before performing the
viability experiments, all cell lines were checked by western blot using 50 mg of protein to confirm their levels of HER3 expression.
doi:10.1371/journal.pone.0053645.g007
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resis (PAGE) gels, electrophoresed at 100 V and electroblotted
onto polyvinylidene difluoride membranes (Merck Millipore,
Billerica, MA) at 0.4 A at room temperature. Blots were blocked
in 5% nonfat dry milk in phosphate-buffered saline (PBS) for 1 h
at room temperature. After blocking, membranes were incubated
overnight with primary antibodies against HER1 (F4, Sigma-
Aldrich); HER2 (CB11, BioGenex, Fremont, CA, USA); HER3
(2F12, NeoMarkers, Fremont, CA); HER4 (111B2), Akt (#9272),
c-catenin (#2309) and Snail (L70G2; all from Cell Signaling,
Beverly, MA, USA); MAPK (C-14), Slug (H-140) and Twist-1 (H-
81; all from Santa Cruz, Heidelberg, Germany); b-actin (A2228,
Sigma-Aldrich); vimentin (V9, Dako, Sant Just Desvern, Spain);
and E-cadherin and b-catenin (Novocastra, Badalona, Spain).
After incubation with horseradish peroxidase-conjugated second-
ary antibodies, antigen-antibody complexes were visualized using
enhanced chemiluminescence (Amersham Biosciences, Dreieich,
Germany). Western blots were repeated in independent conditions
at least twice and representative blots are shown. Densitometrical
quantification of autoradiograms was performed using ImageJ
software (version 1.41o, National Institutes of Health, Bethesda,
MD) by normalizing to the intensity of b-actin in each sample and
are expressed in arbitrary densitometric units.
Immunocytochemistry
Cells were seeded on coverslips at 60% confluence, fixed in 4%
formaldehyde/PBS, permeabilized in 100% methanol for 20 min,
and blocked in 2% BSA for 1 h. Fixed cells were incubated with
anti-E-cadherin (clone 36B5, 1:50) and anti-b-catenin (Novocas-
tra, 1:50), anti-Snail (Cell Signaling, 1:50), anti-Vimentin (Dako,
1:50), and anti-Slug and anti-Twist-1 (Santa Cruz, 1:50) overnight
at 4uC. After washing with PBS, cells were incubated for 1 h in
blocking buffer at room temperature with either 1:800 Alexa Fluor
546 rabbit anti-mouse IgG (Invitrogen, Barcelona, Spain) or 1:200
Alexa Fluor 647 mouse anti-human (Invitrogen). Cells were
washed twice with PBS and once with distilled water. Finally, cells
were mounted in Citifluor (Leicester, UK) before observation and
analysis with fluorescence microscopy.
Immunohistochemical Staining
IHC using the avidin-biotin-peroxidase technique was per-
formed for each antibody. Five-micron-thick sections were cut
from formalin-fixed, paraffin-embedded cell pellets and placed on
poly-L-lysine-coated glass slides. Sections were deparaffinized in
xylene and rehydrated in graded alcohol. Endogenous peroxidase
was blocked by immersing the sections in 0.1% hydrogen
peroxidase in absolute methanol for 20 min. For antigen retrieval,
the tissue sections were heated in a pressure cooker in 10 mM
citric acid monohydrate, pH 6.0, for 5 min, and then incubated
with primary antibodies for 60 min at room temperature. IHC
was performed with the Benchmark XT slide stainer (Ventana
Medical Systems, Inc, Tucson, AZ, USA). The primary antibodies
and dilutions used were: anti-HER3 [generated by Dr. Pandiella
(IBMCC, Salamanca, Spain), 1:75], anti-E-cadherin (Dako, pre-
diluted), anti-b-catenin (Novocastra, 1:50) and anti-vimentin
(Dako, pre-diluted). All slides were hematoxylin counterstained,
dehydrated, and mounted. Negative controls were performed by
omitting the primary antibody and showed minimal non-specific
signal.
Cell Growth Assay
Cells were plated overnight at a density of 50,000 cells/well.
Cell lines were treated with various concentrations of elisidepsin
for 72 h. At least 3 wells were used for each condition and cell
viability was measured by a crystal violet assay. Briefly, cells were
fixed after each treatment in 1% glutaraldehyde for 20 min,
washed twice in PBS, stained with 0.1% crystal violet for 30 min
and then washed with abundant deionized water. Colorant was
recovered using 5% acetic acid and optical density was measured
at 590 nM with an ELISA plate reader.
Plasmids and Cell Transfection
The pIRES-HER3 and the pIRES-Luciferase (LUC) were
kindly donated by Dr. Scaltriti (Vall d’Hebron University Hospital
Research Institute, Barcelona, Spain). The pIRES-LUC was used
as a control for transfection. The pIRES vectors confer
hygromycin resistance. Cells were transfected for 12 h with Jet
Pei (Polyplus-Transfection, Illkirch, France). To eliminate un-
transfected cells and generate stably expressing HER3 cell lines,
medium supplemented with hygromycin (Sigma-Aldrich) was
added 24 h after transfection, and cells underwent selection for
10 days.
Lentivirus shRNA Production and Transduction
Short hairpin RNAs (shRNAs) were used for inhibiting HER3
expression in different cancer cell lines. The following sequences







TACGCGTG, and shHER3_3.3R: AATTCACGCG-
TAAAAAACCAATAC CAGACACTGTACTCTCTTGAAG-
TACAGTGTCTGGTATTGGCG. The different sequences
were cloned into the lentiviral vector pLKO.1 (Sigma-Aldrich).
The pLKO.1-shRNA LUC was used as a control for transfection.
All vectors encode puromycin resistance. Plasmids pVSVG and
pCMVDR8.91 for the expression of packaging and envelope
proteins were kindly provided by Dr. Peeper (VU University
Medical Center, Amsterdam, The Netherlands). Two plates
seeded with 1.56106 HEK 293T cells were co-transfected in
DMEM 10% FBS with 2 mg of pLKO.1, 2 mg of pCMVDR8.91
and 2 mg of pVSVG and incubated overnight. Cells were washed
and incubated in 10% CO2 with medium containing 5% FBS.
After 48 h, the virus-containing supernatant was recovered and
filtered with 0.45 nM filters (Sarstedt, Nümbrecht, Germany).
Titration was performed by infecting cells with the recovered
viral particles in the presence of 4 mg/mL polybrene (Sigma-
Aldrich). Western blot was used to assess the silencing efficacy of
the two shHER3 sequences, and the most effective one
(shHER3.3) was chosen. To obtain cell lines with stable depletion
of HER3, infected cells were selected with puromycin for three
days.
Statistical Analysis
Statistical studies were performed with the Statistical Package
for the Social Sciences (SPSS 15.0; SPSS, Chicago, IL). The
Mann-Whitney test was used to find associations of the parameters
analyzed between two previously selected groups, Sensitive
(includes cell lines with an elisidepsin IC50#1 mM) and Less
Sensitive (includes cell lines with an elisidepsin IC50.1 mM). Cell
growth data are expressed as the mean 6 standard deviation (SD).
Statistical significance was set at a two-tailed p value of 0.05.
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Supporting Information
Figure S1 MCF-7 cells can recover after elisidepsin
treatment. A) Cells were treated with 1 mM of elisidepsin for
4 h, the culture medium was changed and cells were maintained in
the fresh medium for 4, 24, 48 and 72 h. HER1-4 protein
expression levels were analyzed by western blot using 50 mg of
protein from total MCF-7 cell lysates loaded in SDS-PAGE gels.
Membranes were stripped and reprobed with anti-b-actin to verify
equal protein loading. B) Cells were treated with 1 mM of
elisidepsin for 4 h and proliferation was measured by a crystal
violet assay at different time points (white squares) and compared
to untreated cells (black diamonds). Results are expressed as the
mean 6 SD of two independent experiments. C, control.
(TIF)
Figure S2 Statistical analysis of EMT basal expression
levels of breast and pancreas cancer cell lines. Levels of
ErbB3 protein were quantified using western blot analysis (see
Material and Methods) by densitometry. The graph represents the
relative ErbB3 expression in elisidepsin-sensitive (IC50#1 mM) and
-resistant (IC50.1 mM) cell lines. The Mann-Whitney test showed
a statistically significant p value of 0.015.
(TIF)
Figure S3 Elisidepsin cell sensitivity is associated with
HER3 expression levels. Levels of HER1, HER2, HER3 and
HER4 protein were quantified with western blot analysis (Fig. 4)
and subsequent densitometry. Cells that have an elisidepsin IC50
value of #1 mM were considered sensitive to the drug. The graph
represents the HER family members expression relative to
elisidepsin sensitivity. A statistically significance relationship
between HER3 expression levels and elisidepsin sensitivity was
found (Mann-Whitney test: p = 0.0091) but not with the other
members.
(TIF)
Figure S4 Generation and characterization of elisidep-
sin-resistant cell lines from colon and lung. A) Cells were
lysed, proteins were extracted and western blots performed with an
equal amount of cell lysate (50 mg protein). Expression of epithelial
(E-cadherin, b-catenin, c-catenin)- and mesenchymal (vimentin,
Slug, Snail, Twist)-associated proteins differentiates between
elisidepsin-sensitive and elisidepsin-resistant cell lines. b-actin
was used as an internal control. These western blots were
performed in triplicate. B) Expression levels HER1, HER2,
HER3, HER4, pAkt, and pMAPK were analyzed by western
blot using 50 mg of protein cell lysate. The membranes were
stripped and reprobed with anti-b-actin to verify equal protein
loading. HCT 116 (C) and A549 (D) elisidepsin-sensitive cancer
cell lines were rendered resistant by persistent exposure to
increasing concentrations of elisidepsin. Cells were treated with
elisidepsin at the indicated concentrations for 72 h and cell
viability was measured using a crystal violet assay. Error bars show
the SD of three replicate experiments. C, control; R, resistance.
(TIF)
Figure S5 Chemical structure of elisidepsin.
(TIF)
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